Key result
Acarbose reduced the incidence of silent myocardial infarctions compared to placebo in patients with impaired glucose tolerance.
RCT (n=1,181)
randomised
Answers are grounded in this paper and cite their sources.
Supports acarbose consideration to lower silent MI risk in impaired glucose tolerance; extends glucose-lowering evidence to subclinical coronary events.
BACKGROUND: The moderate increase in postprandial plasma glucose in subjects with impaired glucose tolerance has been shown to be a predictor of cardiovascular disease. In the randomised STOP-NIDDM trial, we could demonstrate that lowering postprandial plasma glucose with acarbose in subjects with impaired oral glucose tolerance could reduce the risk of diabetes. METHODS: The current report focuses on the effect of acarbose on silent ischaemic events evaluated in the electrocardiographic substudy, using the Minnesota code classification. RESULTS: A total of 1181 patients were included in the ECG substudy. From these 72 patients had significant changes between the baseline and end of treatment ECG, 33 in the acarbose and 39 in the placebo group. Higher rates of myocardial infarctions occurred in the placebo group (P=0.07 with Fisher's Exact test and P=0.023 with Chi-square test), while there were no differences between the two groups with ECG changes classified under the other Minnesota codes. CONCLUSIONS: In this prospective intervention study we could show that acarbose, by decreasing postprandial hyperglycaemia, can reduce the incidence of silent myocardial infarctions in subjects with impaired glucose tolerance. This approach should therefore be evaluated in other higher risk populations.
No takes yet. Share an insight, caveat, or question.
Zeymer et al. (2004) conducted an RCT in impaired glucose tolerance (n=1,181). Acarbose vs. Placebo was evaluated on Silent myocardial infarctions evaluated by ECG changes (p=0.07 with Fisher's Exact test and 0.023 with Chi-square test). Acarbose reduced the incidence of silent myocardial infarctions compared to placebo in patients with impaired glucose tolerance.
Synapse has enriched 10 related papers. Consider them for comparative context: